Free Trial
→ Buffett's Final Warning: 'The Dollar Is Going to Hell' (From Decentralized Masters) (Ad)tc pixel
NASDAQ:PRAX

Praxis Precision Medicines Q3 2026 Earnings Date & Estimates

Praxis Precision Medicines logo
$243.34 -8.04 (-3.20%)
Closing price 04:00 PM Eastern
Extended Trading
$247.79 +4.45 (+1.83%)
As of 05:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Praxis Precision Medicines is estimated to report Q3 2026 earnings on Monday, November 9, 2026, before market opens. The conference call is scheduled for November 6, 2026 at 12:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
12:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Praxis Precision Medicines in Q3 2026

Praxis Precision Medicines is expected to post earnings of -$3.53 per share on revenue of $0.13 million. In the same quarter a year earlier Praxis Precision Medicines reported -$3.36 per share. Praxis Precision Medicines last reported on August 6, 2026, posting -$2.87 per share and beating the -$3.67 consensus estimate. Praxis Precision Medicines has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$3.53
Expected Revenue
$0.13 million
Prior-Year EPS
-$3.36

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$2.87 (Beat by +$0.80)
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Praxis Precision Medicines Q3 2026 Earnings FAQ

Praxis Precision Medicines (NASDAQ:PRAX) is estimated to report Q3 2026 earnings on Monday, November 9, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Praxis Precision Medicines' Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Praxis Precision Medicines to post earnings of -$3.53 per share for Q3 2026.

The consensus revenue estimate for Praxis Precision Medicines is $0.13 million for Q3 2026.

Praxis Precision Medicines Earnings Headlines

Praxis Precision Medicines (NASDAQ:PRAX) Stock Rating Reaffirmed as "Buy" by HC Wainwright
October 8, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31097964
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/02/3374007/0/en/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
October 13 at 1:00 AM  |  Chaikin Analytics (Ad)
Head-To-Head Comparison: Actinium Pharmaceuticals (NYSE:ATNM) versus Praxis Precision Medicines (NASDAQ:PRAX)
October 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31078241
Praxis Precision Medicines Inc (PRAX)
September 19, 2026  |  in.investing.comhttps://in.investing.com/equities/praxis-precision-medicines-inc-news
Praxis Precision Medicines: Still Potential Upside After Huge Rally (Rating Upgrade)
September 12, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4945791-praxis-precision-medicines-still-potential-upside-after-huge-rally
See More Praxis Precision Medicines Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Praxis Precision Medicines? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Praxis Precision Medicines and other key companies, straight to your email.

About Praxis Precision Medicines

Praxis Precision Medicines (NASDAQ:PRAX) is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders. The company uses insights from human genetics, neuroscience and its Cerebrum™ platform to identify and advance medicines for conditions in which existing treatment options may be limited.

Praxis’ pipeline has included investigational treatments for epilepsies and other neurological disorders, including developmental and epileptic encephalopathies, essential tremor and movement-related conditions. Its research programs include small-molecule medicines designed to modulate neuronal ion channels and antisense oligonucleotide therapies intended to address specific genetic drivers of disease. The company’s drug candidates remain subject to clinical testing and regulatory review.

Founded in 2015 and headquartered in Boston, Massachusetts, Praxis conducts research and clinical development activities through collaborations and studies in the United States and other regions. The company is led by President and Chief Executive Officer Marcio Souza.

View Praxis Precision Medicines Profile
Earnings Tools